What happened
Korea United Pharm updated its previously filed separate results for FY2025: revenue of US$202M (0% year on year), operating profit of US$34.7M (−11.9% year on year) and net income of US$26.8M (+18% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$202M |
|---|---|
| Revenue vs a year earlier | 0% |
| Operating profit | US$34.7M |
| Net income | US$26.8M |
| Period | FY2025 (separate) |
| Filed | 2026-02-26, [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260226801419 → open original filing |
Versions of this filing
- 2026-02-19Original
- 2026-02-26Amendment 1 (this page)
Source: DART. Information only, not investment advice.